BioCrea announced on 9 January that the Epilepsy Foundation (USA) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, GABAA PAMs (LT GABAA PAM), to treat refractory epilepsy
“We are delighted to receive the prestigious Seal award,” says Tom Kronbach, CEO of BioCrea. “This recognition by the Epilepsy Foundation for our work on the LT GABAA PAM platform is highly appreciated. We are impressed that the Foundation’s Scientific Advisory Board and Business Advisory Board do see the potential for our platform to deliver efficacious and novel epilepsy treatments which are currently at candidate selection stage. Having successfully delivered novel treatments for partners such as Pfizer, GlaxoSmithKline, Wyeth and Boehringer Ingelheim, we are well placed to further build our portfolio of projects.”
According to a company release the Epilepsy Foundation states in a letter to BioCrea: “This award is based on the enthusiasm of the Epilepsy Foundation’s Scientific Advisory Broad and Business Advisory Board for the present accomplishments and future potential of this new drug platform that we hope will alleviate the suffering of persons with epilepsy”.
